Home › Companies › AGIOS PHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 18, 2025: 5 items on AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025: 3 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore AGIOS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AGIOS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jacqualyn A. Fouse, Ph.D. | 45,959,402 | -- | -- | 3,925,859 | 1,475,062 | 92% | Not verified | — |
| Elect Director: David Scadden, M.D. | 46,204,689 | -- | -- | 3,680,572 | 1,475,062 | 93% | Not verified | — |
| 2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. | 46,843,926 | 3,024,905 | 16,430 | -- | 1,475,062 | 94% | Approved | — |
| 3. The Company's stockholders approved the 2023 Plan Amendment. | 31,683,420 | 18,197,324 | 4,517 | -- | 1,475,062 | 64% | Approved | — |
| 4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year. | 51,200,808 | 136,734 | 22,781 | -- | 0 | 99.7% | Approved | — |
Source: AGIOS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.
Each item below shows how the 247 asset managers that disclosed a AGIOS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: David Scadden, M.D.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David Scadden, M.D.”): 46,204,689 for, 3,680,572 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,116,254 | 0 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 4,835 | 0 | 0 | 1,151,992 | Withhold |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 106,768 | 0 | 0 | 60,110 | Mixed |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 120,474 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 19,674 | 0 | 0 | 41,500 | Mixed |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 54,918 | Withhold |
| Brighthouse | 52,484 | 0 | 0 | 1,894 | For |
| Columbia Threadneedle | 50,585 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 16,559,197 for, 1,313,512 withheld, 0 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,304,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,304,900 for.
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jacqualyn A. Fouse, Ph.D.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqualyn A. Fouse, Ph.D.”): 45,959,402 for, 3,925,859 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,115,777 | 0 | 0 | 477 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 4,812 | 0 | 0 | 1,152,015 | Withhold |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 106,768 | 0 | 0 | 60,110 | Mixed |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 120,474 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 19,674 | 0 | 0 | 41,500 | Mixed |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 54,918 | 0 | 0 | 0 | For |
| Brighthouse | 52,484 | 0 | 0 | 1,894 | For |
| Columbia Threadneedle | 50,585 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 16,591,020 for, 1,281,689 withheld, 0 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | 2,304,900 | 0 | 0 | Against |
Institutional-manager reports, all 1 managers: 2,304,900 against.
Combines 2 wordings of this item as funds reported it.
64% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE THEREUNDER BY 2,500,000 SHARES.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's stockholders approved the 2023 Plan Amendment.”): 31,683,420 for, 18,197,324 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the 2023 Plan Amendment.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of AGIOS PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (4 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 71 asset managers below reported 14,955,332 for, 2,881,395 against, 1,894 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,112,654 | 3,600 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 1,537,387 | 0 | 0 | Against |
| Fidelity | 1,294,335 | 241,963 | 0 | 0 | Mixed |
| State Street | 1,155,331 | 1,496 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 0 | 280,695 | 0 | 0 | Against |
| AMG FUNDS | 0 | 196,273 | 0 | 0 | Against |
| Equitable | 166,878 | 0 | 0 | 0 | For |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 0 | 120,474 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 47,555 | 13,976 | 0 | 0 | Mixed |
| Lincoln Financial | 41,500 | 19,674 | 0 | 0 | Mixed |
| Invesco | 54,918 | 0 | 0 | 0 | For |
| Brighthouse | 31,140 | 21,344 | 1,894 | 0 | Mixed |
| Columbia Threadneedle | 0 | 50,585 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 47,331 | 0 | 0 | Against |
| John Hancock | 23,868 | 20,060 | 0 | 0 | Mixed |
| ALPS ETF Trust | 0 | 42,419 | 0 | 0 | Against |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 9 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To vote, on an advisory basis, to approve the compensation paid to our named executive officers.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 46,843,926 for, 3,024,905 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,115,777 | 477 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 1,156,827 | 0 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 166,878 | 0 | 0 | 0 | For |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 0 | 120,474 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 61,174 | 0 | 0 | 0 | For |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 0 | 54,918 | 0 | 0 | Against |
| Brighthouse | 52,484 | 0 | 1,894 | 0 | For |
| Columbia Threadneedle | 0 | 50,585 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 17,644,361 for, 226,454 against, 1,894 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 5,072,130 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 2,304,900 | 0 | 0 | 0 | For |
| Commodore Capital LP | 2,291,637 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,288,768 | 0 | 0 | 0 | For |
| State Street | 2,273,044 | 0 | 0 | 0 | For |
| BlackRock | 2,068,213 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,694,299 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,406,164 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 1,279,754 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 964,812 | 0 | 0 | Against |
| JPMorgan | 921,632 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 855,721 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 252,139 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 772,307 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 743,000 | 0 | 0 | 0 | For |
| Caligan Partners LP | 578,827 | 0 | 0 | 0 | For |
| SCS Capital Management LLC | 551,348 | 0 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| Northern Trust | 454,460 | 0 | 0 | 0 | For |
| Artisan | 375,277 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 342,180 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 299,262 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 271,022 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 230,164 | 0 | 0 | Against |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 225,119 | 0 | 0 | Against |
Institutional-manager reports, all 194 managers: 30,444,875 for, 1,930,721 against, 538,079 mixed. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 51,200,808 for, 136,734 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,116,254 | 0 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 1,156,758 | 69 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 166,878 | 0 | 0 | 0 | For |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 120,474 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 61,174 | 0 | 0 | 0 | For |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 54,918 | 0 | 0 | 0 | For |
| Brighthouse | 52,484 | 0 | 1,894 | 0 | For |
| Columbia Threadneedle | 50,585 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 17,854,064 for, 16,751 against, 1,894 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,304,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,304,900 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 57,886,781 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.57% |
| 2 | BlackRock | 4.41% |
| 3 | T. Rowe Price | 3.03% |
| 4 | Delaware/Macquarie | 2.66% |
| 5 | Fidelity | 2.65% |
| 6 | State Street | 2.00% |
| 7 | Charles Schwab | 0.82% |
| 8 | JPMorgan | 0.61% |
| 9 | Artisan | 0.48% |
| 10 | AMG FUNDS | 0.34% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 8.76% |
| 2 | Erste Asset Management GmbH | 3.98% |
| 3 | Commodore Capital LP | 3.96% |
| 4 | T. Rowe Price | 3.95% |
| 5 | State Street | 3.93% |
| 6 | BlackRock | 3.57% |
| 7 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2.93% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.43% |
| 9 | Frazier Life Sciences Management, L.P. | 2.21% |
| 10 | BNP Paribas Asset Management Holding S.A. | 1.67% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 9.68% | 13F |
| BlackRock | 8.83% | 13F |
| Farallon Partners, L.L.C. | 8.72% | 13G |
| Lynx1 Capital Management LP | 5.21% | 13G |
| State Street | 4.23% | 13F |
| T. Rowe Price | 3.98% | 13F |
| Geode Capital | 2.41% | 13F |
| Dimensional Fund Advisors | 2.18% | 13F |
| JPMorgan Chase | 1.81% | 13F |
| Goldman Sachs | 1.14% | 13F |
Percentages above are of 57,886,781 shares outstanding, as reported by AGIOS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AGIOS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At AGIOS PHARMACEUTICALS INC.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 247 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,396 separate fund positions. On the most widely held item on that ballot — To vote, on an advisory basis, to approve the compensation paid to our named executive officers. — AGIOS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AGIOS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.
AGIOS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.